Table 3 Characteristics and medication of IBD patients
Patient | Age in years | Diagnosis | Medication | PUCAI/PCDAI before 8-week intervention | PUCAI/PCDAI after 8-week intervention |
|---|---|---|---|---|---|
1 | 14.16 | Crohn’s disease | Infliximab 5 mg/kg 6-weekly and Azathioprine 100 mg/ day | 25 | 15 |
2 | 17.08 | Crohn’s disease | Infliximab 5 mg/kg 6-weekly | 30 | 25 |
3 | 11.75 | Ulcerative colitis | Azathioprine 100 mg/day | 0 | 0 |
4 | 17.16 | Crohn’s disease | Ustekinumab 45 mg s.c. 8-weekly | 5 | 5 |
5 | 13.41 | Ulcerative colitis | Golimumab 50 mg s.c. every 4-weekly | 0 | 5 |
6 | 14.16 | Crohn’s disease | Mesalazine 2 g/day | 0 | 5 |
7 | 13.83 | Crohn’s disease | Azathioprine 75 mg daily | 0 | 0 |
8 | 12.58 | Ulcerative colitis | Golimumab 50 mg 4-weekly | 25 | 20 |
9 | 13.66 | Crohn’s disease | Infliximab 5 mg/kg 8-weekly Azathioprine 100 mg/day | 5 | 0 |
10 | 12.33 | Crohn’s disease | Infliximab 5 mg/kg 8-weekly | 5 | 0 |
11 | 16.33 | Crohn’s disease | Azathioprine 75 mg/day | 0 | 0 |
12 | 17.75 | Ulcerative colitis | Azathioprine 100 mg/day | 25 | 20 |
13 | 4.58 | Ulcerative colitis | Mesalazine 500 mg/day | 0 | 0 |
14 | 23.16 | Ulcerative colitis | no treatment at this time | 0 | 0 |
15 | 17.33 | Crohn’s disease | Infliximab 5 mg/kg 7-weekly | 20 | 15 |
16 | 7.58 | Ulcerative colitis | Mesalazine 1 g/day Prednisone 20 mg/10 mg/day | 40 | 30 |
17 | 15.33 | Crohn’s disease | Infliximab 5 mg/kg 8weekly | 5 | 0 |
18 | 14.16 | Indeterminate colitis | Infliximab 10 mg/kg 6-weekly | 0 | 5 |
19 | 3.0 | Ulcerative colitis | Mesalazine 500 mg/day Prednisone 15 mg/day | 15 | 10 |
20 | 10.66 | Ulcerative colitis | Mesalazine 1 g/ day | 0 | 0 |
21 | 10.5 | Crohn’s disease | no treatment at this point | 5 | 5 |